Lattice Biologics(OTC) LBLTF

Lattice Biologics Ltd. is a biotechnology firm dedicated to developing, manufacturing, and commercializing biological products for bone regeneration. The company’s innovative solutions are utilized globally in dental, spinal, and orthopedic applications.

Products and Services

• Amniotic fluid-based therapies, including AmnioBoost and AmnioBlast
• A diverse range of allografts for various medical applications
• Products supporting spinal fusion, wound repair, and orthopedic surgeries

Growth Outlook

• Focus on expanding product offerings in the regenerative medicine market
• Potential for increased demand in orthopedic and dental sectors
• Strategic partnerships may enhance market reach and innovation

Financial Highlights

• Recent quarterly revenue of 287,653, showing potential for growth
• Trailing twelve months (TTM) gross profit margin at 41.4%
• Operating cash flow improved, indicating better cash management

Lattice Biologics Ltd. operates in the medical devices industry, focusing on innovative solutions for bone regeneration. The company’s product line includes advanced therapies that cater to a wide range of medical needs, from spinal surgeries to wound healing. The growth outlook appears promising, with an emphasis on expanding product offerings and potential partnerships that could enhance market presence. Recent financial data indicates a revenue of 287,653 in the latest quarter, reflecting a positive trend in sales. The TTM gross profit margin stands at 41.4%, suggesting effective cost management and operational efficiency. Additionally, improvements in operating cash flow highlight the company's efforts to enhance financial stability. Overall, Lattice Biologics Ltd. presents an intriguing opportunity within the biotechnology sector, particularly for those interested in innovative medical solutions.